Results 191 to 200 of about 139,987 (302)

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study. [PDF]

Blood Adv
Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet M, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, André M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas-Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens MC, Griolet S, Gaulard P, Delfau-Larue MH, de Leval L, Damaj GL.   +42 more
europepmc   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

The evolving role of regulatory T cells in Sjögren's disease pathogenesis and the promise of Treg‐based therapies: A comprehensive review

Rheumatology &Autoimmunity, EarlyView.
Graphical Abstract The evolving role of regulatory T cells in primary Sjögren's disease pathogenesis and the promise of Treg‐based therapies. Abstract Sjögren's disease (SjD) is a chronic systemic autoimmune disorder characterised by exocrine gland dysfunction and diverse systemic manifestations.
Gagan Urs, Bharath Raj Srinivasan, Himabindu Jayaprakash Narayan, Mirunalini Gobinath, Lekitha Manjunath, Mahabaleshwar Mamadapur   +5 more
wiley   +1 more source

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database. [PDF]

J Pharm Health Care Sci
Takatsu N, Matsumoto J, Oka Y, Sakai T, Iwata N, Higashionna T, Takeda T, Hamano H, Zamami Y.   +8 more
europepmc   +1 more source

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma. [PDF]

Blood Adv
Khan N, Dahi PB, Khimani F, Shustov AR, Shadman M, Ruan J, Moskowitz AJ, Zelenetz AD, Noy A, Straus DJ, Drullinsky P, Hamilton A, Kumar A, Sauter CS, Shah GL, Matasar MJ, Drill E, Davey T, Hancock H, Ganesan N, Galasso N, van Beisen K, Giralt S, Horwitz SM.   +23 more
europepmc   +1 more source

Biomaterial‐Integrated Electroporation for Therapeutic Delivery: From Gene Editing to Tumor Ablation and Immune Modulation

Small, EarlyView.
Biomaterial‐integrated electroporation establishes a programmable therapeutic interface that coordinates electric‐field modulation, transient or irreversible membrane permeabilization, cargo stabilization, and immune remodeling. This Review highlights how nanocarriers, hydrogels, and bioelectronic interfaces expand electroporation from conventional ...
Binbin Ji, Zhuozhuo Wu, Yuyue Jiang, Xiaoyu Liu, Jingfeng Li, Fengkuo Xu, Chaojie Li, Qungang Shan, Ziyin Wang, Junhao Wang, Wei Huang, Yaping Zhuang, Wenguo Cui, Zhongmin Wang   +13 more
wiley   +1 more source

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study. [PDF]

J Dtsch Dermatol Ges
Glatzel C, Hansen-Abeck I, Booken N, Düll J, Goebeler M, Schummer P, Wobser M.   +6 more
europepmc   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma. [PDF]

Front Immunol
Huang L, Guo H, Teng Y, Pang D, Zhang F, Sun Y, Ong CK, Tan J, Li W.   +8 more
europepmc   +1 more source

Successful allo‐hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product

Pediatric Investigation, EarlyView.
Jieyu Tian, Guanghua Zhu, Maoquan Qin, Chenguang Jia, Shuxuan Ma, Bin Wang, Yanhui Luo   +6 more
wiley   +1 more source